Gland Pharma Gets US FDA Nod for Generic Sugammadex Injection
Source: ET Real Estate
Arth Insight · What this means for your wallet
- Gland Pharma's generic sugammadex injection approved by USFDA.
- The drug reverses muscle relaxant effects used in surgery.
- The generic is bioequivalent to Merck's BRIDION injection.
Wealth-Impact Simulator
See how a change in interest rates hits your loan EMI.
Indicative estimate for education only — not investment advice.
Compare loan ratesGland Pharma has received US FDA approval for its generic version of sugammadex injection, a drug used to reverse muscle relaxants during surgery. This approval marks a significant step for the company in the US market.
- ▸Gland Pharma's generic sugammadex injection approved by USFDA.
- ▸The drug reverses muscle relaxant effects used in surgery.
- ▸The generic is bioequivalent to Merck's BRIDION injection.
- ▸This approval could boost Gland Pharma's US market presence.
- ✓Gland Pharma's generic sugammadex injection approved by USFDA.
- ✓The drug reverses muscle relaxant effects used in surgery.
- ✓The generic is bioequivalent to Merck's BRIDION injection.
- ✓This approval could boost Gland Pharma's US market presence.
Gland Pharma has secured approval from the United States Food and Drug Administration (USFDA) for its generic sugammadex injection. This drug plays a crucial role in surgical procedures by reversing the effects of muscle relaxants administered to patients.
The USFDA approval covers two specific strengths of the single-dose vial product. The newly approved generic injection is bioequivalent to Merck's original BRIDION injection, indicating comparable efficacy and safety. The market for sugammadex injection in the US has shown significant sales in the past year, suggesting a substantial demand for such pharmaceutical products.
This development is a positive step for Gland Pharma, potentially expanding its product portfolio and market reach in the United States. The company's ability to bring generic versions of critical drugs to market highlights its manufacturing capabilities and its role in making healthcare more accessible.
This report is for informational purposes only and does not constitute investment advice.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What is sugammadex injection used for?
Sugammadex injection is used to reverse the effects of muscle relaxant drugs that are administered during surgical procedures.
Which company's product is Gland Pharma's generic equivalent to?
Gland Pharma's generic sugammadex injection is bioequivalent to Merck's BRIDION injection.
What does USFDA approval signify?
USFDA approval means the drug has met the stringent safety and efficacy standards set by the United States Food and Drug Administration, allowing it to be marketed and sold in the US.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
GCCs to Drive Nearly Half of India's Office Leasing by 2026
Global Capability Centres (GCCs) are set to dominate India's office leasing market, potentially accounting for almost half of all space leased by 2026. In the first half of 2026, GCCs leased 16.6 million sq ft of Grade A office space, representing 46% of total leasing across seven major Indian cities.
Aster DM Healthcare to Invest ₹1,315 Crore to Expand Hospitals in Karnataka
Aster DM Quality Care has announced a massive ₹1,315 crore investment to boost healthcare infrastructure in Karnataka. The funds will be used to build new hospitals and upgrade existing facilities in Bengaluru to provide advanced medical care.
IPOBreakingManipal Health to Invest ₹4,000 Crore for 2,400 New Beds Ahead of IPO
Manipal Health Enterprises plans to invest ₹4,000 crore over the next 3-4 years to add 2,400 hospital beds, increasing its capacity by over 18%. This significant expansion comes just before its anticipated Initial Public Offering (IPO) next week.
Related Stories
GCCs to Drive Nearly Half of India's Office Leasing by 2026
Global Capability Centres (GCCs) are set to dominate India's office leasing market, potentially accounting for almost half of all space leased by 2026. In the first half of 2026, GCCs leased 16.6 million sq ft of Grade A office space, representing 46% of total leasing across seven major Indian cities.
Aster DM Healthcare to Invest ₹1,315 Crore to Expand Hospitals in Karnataka
Aster DM Quality Care has announced a massive ₹1,315 crore investment to boost healthcare infrastructure in Karnataka. The funds will be used to build new hospitals and upgrade existing facilities in Bengaluru to provide advanced medical care.
IPOBreakingManipal Health to Invest ₹4,000 Crore for 2,400 New Beds Ahead of IPO
Manipal Health Enterprises plans to invest ₹4,000 crore over the next 3-4 years to add 2,400 hospital beds, increasing its capacity by over 18%. This significant expansion comes just before its anticipated Initial Public Offering (IPO) next week.
BreakingTrump's Proposed 200% Tariff Threatens $9.7 Billion Indian Pharma Exports by 2028
Former US President Donald Trump's proposed 200% tariff on imported generic drugs could put India's significant $9.7 billion generic drug exports to the United States at risk starting 2028. Indian pharmaceutical companies have a two-year window to explore new markets and adapt, while US patients and insurers may face increased healthcare costs.
